Advertisement

Hepatitis D Virus

  • Mario Rizzetto
Chapter

Abstract

Hepatitis D is caused by the hepatitis D virus (HDV), a ubiquitous RNA agent which depends upon the envelope proteins of the hepatitis B virus (HBV) for assembly of progeny virus. The infection is transmitted parenterally as well as sexually. Intravenous drug users are at the highest risk of infection. HBV infected patients who become superinfected with HDV are the major reservoir of the virus due to the high rate of chronicity. With the advent of universal HBV vaccination, the incidence of hepatitis D has declined in developed and developing countries. Residual disease persists in the aging domestic population of Southern Europe and in injection drug users and immigrants throughout Europe and the United States, with high concentrations in Mongolia and northwestern Amazonia as well as pockets of high-risk people in other countries. The prevalence of hepatitis D remains high and has a major medical impact in many areas of the developing world where HBV remains endemic and not controlled.

Keywords

Hepatitis D virus Hepatitis delta virus Hepatitis D epidemiology HBsAg 

References

  1. 1.
    Rizzetto M. The delta agent. Hepatology. 1983;3:729–37.CrossRefGoogle Scholar
  2. 2.
    Rizzetto M, et al. Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res. 1991;364:1–20.PubMedGoogle Scholar
  3. 3.
    Rizzetto M, et al. Hepatitis delta virus as a global health problem. Vaccine. 1990;8(Suppl 8):S10–4.CrossRefGoogle Scholar
  4. 4.
    Rizzetto M, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. 1983;98:437–41.CrossRefGoogle Scholar
  5. 5.
    Fattovich G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46:420–6.CrossRefGoogle Scholar
  6. 6.
    Smedile A, et al. Advances in hepatitis D virus biology and disease. In: Boyer JL, Ockner RK, editors. Progress in liver disease, vol. XII. Philadelphia, PA: WB Saunders; 1994. p. 157–75.Google Scholar
  7. 7.
    Taylor JM. Structure and replication of hepatitis delta virus RNA. Curr Top Microbiol Immunol. 2006;307:1–23.PubMedGoogle Scholar
  8. 8.
    Tseng CH, Lai MM. Hepatitis delta virus RNA replication. Viruses. 2009;1:818–31.CrossRefGoogle Scholar
  9. 9.
    Ponzetto A, et al. Titration of the infectivity of hepatitis D virus in chimpanzees. J Infect Dis. 1987;155:72–8.CrossRefGoogle Scholar
  10. 10.
    Tamura I, et al. Hepatitis delta virus infection in different time periods in Japan. J Gastroenterol Hepatol. 1990;5:407–10.CrossRefGoogle Scholar
  11. 11.
    Kim HS, et al. Prevalence and clinical significance of hepatitis D virus co-infection in patients with chronic hepatitis B in Korea. J Med Virol. 2011;83:1172–7.CrossRefGoogle Scholar
  12. 12.
    Le Gal F. Eighth major clade for hepatitis delta virus. Emerg Infect Dis. 2006;12:1447–50.CrossRefGoogle Scholar
  13. 13.
    Barros LM, et al. Hepatitis delta virus genotype 8 infection in Northeast Brazil: inheritance from African slaves? Virus Res. 2011;160:333–9.CrossRefGoogle Scholar
  14. 14.
    Casey JL, et al. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A. 1993;90:9016–20.CrossRefGoogle Scholar
  15. 15.
    Wu JC. Functional and clinical significance of hepatitis D virus genotype II infection. Curr Top Microbiol Immunol. 2006;307:173–86.PubMedGoogle Scholar
  16. 16.
    Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211–9.CrossRefGoogle Scholar
  17. 17.
    Negro F. Hepatitis D virus coinfection and superinfection. In: Seeger C, Locarnini S, editors. The hepatitis B and delta viruses, Cold Spring Harbor perspectives in medicine. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2015. p. 329–37.Google Scholar
  18. 18.
    Farci P. Delta hepatitis: an update. J Hepatol. 2003;39(Suppl 1):212–9.CrossRefGoogle Scholar
  19. 19.
    Olivero A, Smedile A. Hepatitis delta virus diagnosis. Semin Liver Dis. 2012;32:220–7.CrossRefGoogle Scholar
  20. 20.
    Chudy M, et al. Collaborative study to establish a World Health Organization International Standard for Hepatitis D Virus RNA for Nucleic Acid Amplification Technology (NAT)—based assays. WHO Report 2013, WHO/BS/2013.2.227.Google Scholar
  21. 21.
    Le Gal F, et al. First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology. 2016;64:1483–94.CrossRefGoogle Scholar
  22. 22.
    Liaw YF, et al. Hepatitis delta virus infection in Taiwan. Prog Clin Biol Res. 1987;234:479–83.PubMedGoogle Scholar
  23. 23.
    Hadler SC, et al. An epidemic of severe hepatitis due to delta virus infection in Yupca Indians in Venezuela. Ann Intern Med. 1984;100:339–44.CrossRefGoogle Scholar
  24. 24.
    Lesbordes JL, et al. Studies on the role of HDV in an outbreak of fulminant hepatitis in Bangui (Central African Republic). Prog Clin Biol Res. 1987;234:451–9.PubMedGoogle Scholar
  25. 25.
    Khuroo MS, et al. An epidemic of hepatitis D in the foothills of the Himalayas in south Kashmir. J Hepatol. 1988;7:151–6.CrossRefGoogle Scholar
  26. 26.
    Flodgren E, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol. 2000;38:3311–6.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Børresen ML, et al. Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat. 2010;17:162–70.CrossRefGoogle Scholar
  28. 28.
    Davaalkham D, et al. Hepatitis delta virus infection in Mongolia: analyses of geographic distribution, risk factors and disease severity. Am J Trop Med Hyg. 2006;75:365–9.CrossRefGoogle Scholar
  29. 29.
    Amini N, et al. Prevalence of hepatitis D in the eastern Mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13:e8210.CrossRefGoogle Scholar
  30. 30.
    Degertekin HY, et al. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;28:494–8.CrossRefGoogle Scholar
  31. 31.
    Abbas Z, et al. Hepatitis D: scenario in the Asia-Pacific region. World J Gastroenterol. 2010;16:554–62.CrossRefGoogle Scholar
  32. 32.
    Kozhanova TV, et al. [Familial clusters of hepatitis delta in endemic region (republic tyva)]. Eksp Klin Gastroenterol. 2015;(11):15–22.Google Scholar
  33. 33.
    Kozhanova TV, et al. [Viral hepatitis delta. Is there the delta infection problem in the Russian Federation?]. Eksp Klin Gastroenterol. 2014;(12):4–12.Google Scholar
  34. 34.
    Mumtaz K, et al. Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J. 2011;8:312.  https://doi.org/10.1186/1743-422X-8-312.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Alavian SM, Alavian SH. Hepatitis D virus infection; Iran, Middle East and Central Asia. Hepat Mon. 2005;5:137–43.Google Scholar
  36. 36.
    Sy BT, et al. High prevalence and significance of hepatitis D virus infection among treatment-naıve HBsAg-positive patients in northern Vietnam. PLoS One. 2013;8:e78094.CrossRefGoogle Scholar
  37. 37.
    Hall N, et al. High prevalence of hepatitis delta virus among persons who inject drugs, Vietnam. Emerg Infect Dis. 2015;21:540–3.CrossRefGoogle Scholar
  38. 38.
    Inoue J, et al. High prevalence of hepatitis delta virus infection detectable by enzyme immunoassay among apparently healthy individuals in Mongolia. J Med Virol. 2005;76:333–40.CrossRefGoogle Scholar
  39. 39.
    Chen X, et al. A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians. Hepatology. 2017;66(6):1739–49.  https://doi.org/10.1002/hep.28957.CrossRefPubMedGoogle Scholar
  40. 40.
    Patel FM, Goswami PN. Presence of acute hepatitis D infection in HBsAg positive cancer patients: a preliminary study from west Gujarat. Indian J Med Res. 2016;143:798–800.CrossRefGoogle Scholar
  41. 41.
    Jat SL, et al. Prevalence of hepatitis D virus infection among hepatitis B virus-infected individuals in India. Indian J Gastroenterol. 2015;34:164–8.CrossRefGoogle Scholar
  42. 42.
    Acharya SK, et al. Viral hepatitis in India. Natl Med J India. 2006;19:203–17.PubMedGoogle Scholar
  43. 43.
    Liao B, et al. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One. 2014;9:e115888.CrossRefGoogle Scholar
  44. 44.
    Han M, et al. Molecular epidemiology of hepatitis delta virus in the western Pacific region. J Clin Virol. 2014;61:34–9.CrossRefGoogle Scholar
  45. 45.
    Andernach IE, et al. Characterization of hepatitis delta virus in sub-saharan Africa. J Clin Microbiol. 2014;52:1629–36.CrossRefGoogle Scholar
  46. 46.
    Makula M, et al. Prevalence and molecular diversity of hepatitis B virus and hepatitis delta virus in urban and rural populations in northern Gabon in Central Africa. J Clin Microbiol. 2009;47:2265–8.CrossRefGoogle Scholar
  47. 47.
    Makuwa M, et al. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in Central Africa. J Clin Microbiol. 2008;46:754–6.CrossRefGoogle Scholar
  48. 48.
    Foupouapouognigni Y, et al. High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon. J Clin Microbiol. 2011;49:1162–4.CrossRefGoogle Scholar
  49. 49.
    Birguel J, et al. Viral markers of hepatitis B, C and D and HB vaccination status of a health care team in a rural district of Cameroon. Med Trop. 2011;71:201–2.Google Scholar
  50. 50.
    Mansour W, et al. Virological and epidemiological features of hepatitis delta infection among blood donors in Nouakchott, Mauritania. J Clin Virol. 2012;55:12–6.CrossRefGoogle Scholar
  51. 51.
    Mansour W, et al. Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania. J Med Virol. 2012;84:1186–98.CrossRefGoogle Scholar
  52. 52.
    Vray M, et al. Molecular epidemiology of hepatitis B virus in Dakar, Sénégal. J Med Virol. 2006;78:329–34.CrossRefGoogle Scholar
  53. 53.
    De Paschale M, et al. Prevalence of HBV, HDV, HCV, and HIV infection during pregnancy in northern Benin. J Med Virol. 2014;86:1281–7.CrossRefGoogle Scholar
  54. 54.
    Asmah RH, et al. Prevalence of hepatitis d infection in patients with hepatitis B virus-related liver diseases in Accra, Ghana. West Afr J Med. 2014;33:32–6.PubMedGoogle Scholar
  55. 55.
    Nwokediuko SC, Ijeoma U. Seroprevalence of antibody to HDV in Nigerians with hepatitis B virus-related liver diseases. Niger J Clin Pract. 2009;12:439–42.PubMedGoogle Scholar
  56. 56.
    Amougou MA, et al. A prominent role of hepatitis D virus in liver cancers documented in Central Africa. BMC Infect Dis. 2016;16:647.CrossRefGoogle Scholar
  57. 57.
    Braga WS, et al. Hepatitis D virus infection in the western Brazilian Amazon—far from a vanishing disease. Rev Soc Bras Med Trop. 2012;45:691–5.CrossRefGoogle Scholar
  58. 58.
    di Filippo Villa D, et al. Hepatitis D virus and hepatitis B virus infection in Amerindian communities of the Amazonas state, Colombia. Virol J. 2015;12:172.  https://doi.org/10.1186/s12985-015-0402-5.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Ramia S, et al. Delta agent infection in Riyadh, Saudi Arabia. Trans R Soc Trop Med Hyg. 1987;81:317–8.CrossRefGoogle Scholar
  60. 60.
    Greenfield C, et al. Hepatitis delta virus infection in Kenya. Its geographic and tribal distribution. Am J Epidemiol. 1986;123:416–23.CrossRefGoogle Scholar
  61. 61.
    Hadziyannis SJ. Decreasing prevalence of hepatitis D virus infection. J Gastroenterol Hepatol. 1997;12:745–6.CrossRefGoogle Scholar
  62. 62.
    Gaeta GB, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000;32:824–7.CrossRefGoogle Scholar
  63. 63.
    Lin HH, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015;61:1870–9.CrossRefGoogle Scholar
  64. 64.
    Wedemeyer H, et al. Hepatitis D virus infection—not a vanishing disease in Europe! Hepatology. 2007;45:1331–2.CrossRefGoogle Scholar
  65. 65.
    Stroffolini T, et al. Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol. 2009;81:1999–2006.CrossRefGoogle Scholar
  66. 66.
    Cross TJ, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in south London. J Med Virol. 2008;80:277–82.CrossRefGoogle Scholar
  67. 67.
    Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40.CrossRefGoogle Scholar
  68. 68.
    Servant-Delmas A, et al. Increasing prevalence of HDV/HBV infection over 15 years in France. J Clin Virol. 2014;59:126–8.CrossRefGoogle Scholar
  69. 69.
    Ordieres C, et al. Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from northern Spain. Eur J Gastroenterol Hepatol. 2017;29:277–83.CrossRefGoogle Scholar
  70. 70.
    Shadur B, et al. Hepatitis D virus in Victoria 2000–2009. Intern Med J. 2013;43:1081–7.CrossRefGoogle Scholar
  71. 71.
    Rizzetto M, Alavian SM. Hepatitis delta: the rediscovery. Clin Liver Dis. 2013;17:475–87.CrossRefGoogle Scholar
  72. 72.
    Rizzetto M. Hepatitis D virus: introduction and epidemiology. Cold Spring Harb Perspect Med. 2015;5(7):a021576.CrossRefGoogle Scholar
  73. 73.
    Genné D, Rossi I. Hepatitis delta in Switzerland: a silent epidemic. Swiss Med Wkly. 2011;141:w13176.PubMedGoogle Scholar
  74. 74.
    Heidrich B, et al. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009;16:883–94.CrossRefGoogle Scholar
  75. 75.
    Riaz F, et al. An overview of triple infection with hepatitis B, C and D viruses. Virol J. 2011;8:368.  https://doi.org/10.1186/1743-422X-8-368.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Raimondo G, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100–7.CrossRefGoogle Scholar
  77. 77.
    Calle Serrano B, et al. Hepatitis delta and HIV infection. Semin Liver Dis. 2012;32:120–9.CrossRefGoogle Scholar
  78. 78.
    Hung CC, et al. Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin Infect Dis. 2014;58:1625–33.CrossRefGoogle Scholar
  79. 79.
    Hsieh MH, et al. Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan. Kaohsiung J Med Sci. 2016;32:526–30.CrossRefGoogle Scholar
  80. 80.
    Fernández-Montero JV, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–53.CrossRefGoogle Scholar
  81. 81.
    Kushner T, et al. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586–92.CrossRefGoogle Scholar
  82. 82.
    NHANES IV-Hepatitis Laboratory Results: Center for Disease Control 2003–2004.Google Scholar
  83. 83.
    Bialek SR, et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health. 2005;82:468–78.CrossRefGoogle Scholar
  84. 84.
    Kucirka LM, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845–52.CrossRefGoogle Scholar
  85. 85.
    Gish RG, et al. Co-infection with hepatitis B and D: epidemiology, prevalence and disease in patients in northern California. J Gastroenterol Hepatol. 2013;28:1521–5.CrossRefGoogle Scholar
  86. 86.
    Rizzetto M. Hepatitis D: clinical features and therapy. Dig Dis. 2010;28:139–43.CrossRefGoogle Scholar
  87. 87.
    Rosina F, et al. Changing pattern of chronic hepatitis D in southern Europe. Gastroenterology. 1999;117:161–6.CrossRefGoogle Scholar
  88. 88.
    Buti M, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18:434–42.CrossRefGoogle Scholar
  89. 89.
    Abbas Z, et al. Hepatitis D and hepatocellular carcinoma. World J Hepatol. 2015;7:777–86.CrossRefGoogle Scholar
  90. 90.
    Ji J, et al. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:790–2.CrossRefGoogle Scholar
  91. 91.
    Roggendorf M. Perspectives for a vaccine against hepatitis delta virus. Semin Liver Dis. 2012;32:256–61.CrossRefGoogle Scholar
  92. 92.
    Rizzetto M. Targeting hepatitis D. Semin Liver Dis. 2018;38:66–72. https://doi.org/10.1055/s-0037-1621711. Epub 2018.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Mario Rizzetto
    • 1
  1. 1.Division of GastroenterologyUniversity of TorinoTorinoItaly

Personalised recommendations